FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals
WASHINGTON, D.C. — The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). The product […]